In IDH1 mutant mouse bone marrow cells, vitamin C (added daily at 100 μg/mL corresponding to 0.325 mM, in the form of 2-phosphate L-ascorbic acid) was found to overcome the effects of IDH1 mutations, promoting DNA demethylation and epigenetic remodeling of transcription factor-binding sites through stimulation of TET2 activity with consequent induction of leukemia cell differentiation [108]. The gene discussed is TET2; the disease is leukemia.